{"organizations": [], "uuid": "acee4fa728e3ca25acfe4bf5e37af87cc8729776", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-immunoprecise-signs-agreement-to-b/brief-immunoprecise-signs-agreement-to-buy-modiquest-research-idUSFWN1QY0IW", "country": "US", "domain_rank": 408, "title": "BRIEF-Immunoprecise Signs Agreement To Buy Modiquest Research", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-16T14:41:00.000+02:00", "replies_count": 0, "uuid": "acee4fa728e3ca25acfe4bf5e37af87cc8729776"}, "author": "", "url": "https://www.reuters.com/article/brief-immunoprecise-signs-agreement-to-b/brief-immunoprecise-signs-agreement-to-buy-modiquest-research-idUSFWN1QY0IW", "ord_in_thread": 0, "title": "BRIEF-Immunoprecise Signs Agreement To Buy Modiquest Research", "locations": [], "entities": {"persons": [{"name": "immunoprecise", "sentiment": "none"}], "locations": [], "organizations": [{"name": "modiquest research", "sentiment": "negative"}, {"name": "modiquest research reuters", "sentiment": "negative"}, {"name": "immunoprecise antibodies ltd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 44 PM / in 11 minutes BRIEF-Immunoprecise Signs Agreement To Buy Modiquest Research Reuters Staff   Immunoprecise Antibodies Ltd: * IMMUNOPRECISE ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE MODIQUEST RESEARCH BV * IMMUNOPRECISE ANTIBODIES LTD - ‍IMMUNOPRECISE WILL PAY A TOTAL OF EUR 7,000,000​ * IMMUNOPRECISE - AGREED TO ACQUIRE ALL OF ISSUED AND OUTSTANDING SHARES OF MODIQUEST AND IMMULEASE​ * IMMUNOPRECISE ANTIBODIES LTD - ‍ WILL COMPLETE A DEBENTURE FINANCING IN PRINCIPAL AMOUNT OF UP TO CAD $4.1 MILLION * IMMUNOPRECISE - ‍PURCHASE PRICE TO BE PAID USING EUR 2,500,000 IN CASH, 6,600,399 SHARES OF IMMUNOPRECISE ​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-16T14:41:00.000+02:00", "crawled": "2018-03-16T15:01:43.028+02:00", "highlightTitle": ""}